

Edgar Filing: MEDIMMUNE INC /DE - Form 10-Q

MEDIMMUNE INC /DE
Form 10-Q
August 03, 2001

SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D. C. 20549

FORM 10-Q

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCH

For the quarterly period ended June 30, 2001

Commission File No. 0-19131

MedImmune, Inc.

(Exact name of registrant as specified in its charter)

Delaware
(State or other jurisdiction of
incorporation or organization)

52-1555759
(I. R. S. Employer
Identification No.)

35 West Watkins Mill Road, Gaithersburg, MD 20878
(Address of principal executive offices) (Zip Code)

Registrant's telephone number, including area code (301) 417-0

Indicate by check mark whether the Registrant (1) has filed all reports required to be filed
Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period
required to file such reports) and (2) has been subject to such filing requirements for the past

As of June 30, 2001, 213,733,442 shares of Common Stock, par value \$0.01 per share, were outstand

MEDIMMUNE, INC.
Index to Form 10-Q

Part I Financial Information

Edgar Filing: MEDIMMUNE INC /DE - Form 10-Q

Item 1. Financial Statements

Balance Sheets
Statements of Operations
Condensed Statements of Cash Flows
Notes to Financial Statements

Item 2. Management's Discussion and Analysis of Financial Condition
and Results of Operations

Item 3. Quantitative and Qualitative Disclosures about Market Risk

Part II Other Information

Item 1. Legal Proceedings

Item 2. Changes in Securities

Item 3. Defaults upon Senior Securities

Item 4. Submission of Matters to a Vote of Security Holders

Item 5. Other Information

Item 6. Exhibits and Reports on Form 8-K

Synagis, CytoGam, Ethyol, RespiGam, and NeuTrexin are registered trademarks of the Compa